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Abstract
Autism is a dynamic neurodevelopmental syndrome in which disabilities emerge during the first
three postnatal years and continue to evolve with ongoing development. We briefly review research
in autism describing subtle changes in molecules important in brain development and
neurotransmission, in morphology of specific neurons, brain connections and in brain size. We then
provide a general schema of how these processes may interact with particular emphasis on
neurotransmission. In this context, we present a rationale for utilizing pharmacologic treatments
aimed at modifying key neurodevelopmental processes in young children with autism. Early
treatment with selective serotonin reuptake inhibitors (SSRIs) is presented as a model for
pharmacologic interventions because there is evidence in autistic children for reduced brain serotonin
synthesis during periods of peak synaptogenesis; serotonin is known to enhance synapse refinement;
and exploratory studies with these agents in autistic children exist. Additional hypothetical
developmental interventions and relevant published clinical data are described. Finally, we discuss
the importance of exploring early pharmacologic interventions within multiple experimental settings
in order to develop effective treatments as quickly as possible while minimizing risks.
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Autism is the prototypical neurodevelopmental disorder. It is characterized by qualitative
alterations in three behavioral areas: social reciprocity, communication, and breadth of interests
manifest by repetitive behaviors or restricted interests. Individuals with autism also experience
a number of frequently associated behavioral problems such as hyperactivity, impulsivity,
anxiety, irritability, and aggression, which are often the focus of pharmacologic interventions
(Findling 2005; Sikich 2001). General cognitive deficits are common with approximately 60
– 70% of affected individuals considered mentally retarded (Bertrand et al 2001; Chakrabarti
and Fombonne 2005; Fombonne et al 2003) and notable within subject variability in specific
cognitive abilities (Joseph et al 2002). Four times as many males as females are affected
(Chakrabarti and Fombonne 2005). The extreme diversity of clinical presentations is striking.
Signs of the disorder begin to emerge during the first three years of life and sufficient symptoms
are frequently present in the core diagnostic areas to reliably diagnose the disorder by age two
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years (Lord et al 2006). Yet, the specific behavioral manifestations of autism change across
the life span suggesting ongoing developmental effects that impact prognosis.
Despite intensive research using a variety of techniques, the pathophysiology of autism remains
largely unknown. Although individual investigations from various research fields have
produced intriguing results, none of the studies have been definitive and discrepant findings
are often present among different populations and protocols. Some of these discrepancies may
be related to etiologic heterogeneity. For instance, distinct genetic loci have been implicated
among males and females with clinically indistinguishable autism (Schellenberg et al 2006).
Further genetic models suggest that multiple genes may interact to result in the full phenotype
(Pickles et al 1995; Risch et al 1999). Taken together, these findings suggest common
developmental pathways may be disrupted at multiple points and that multiple disruptions may
be needed to result in the full clinical manifestations of autistic syndrome. Because autism is
highly heritable (Bailey et al 1995; Folstein and Piven 1991; Folstein and Rosen-Sheidley
2001), considerable efforts have been expended to identify vulnerability genes (Klauck
2006; Muhle 2004). Several genes with neurodevelopmental functions have been proposed as
candidate genes (Polleux and Lauder 2004). In addition, several molecules relevant to
neurodevelopment and neurotransmission appear to vary between some individuals with
autism and controls using a variety of assessment methods including positron emission
transmission scanning (PET), blood and urine analyses, and examination of postmortem
samples. Limited neuropathologic data has identified subtle differences in morphology and
organization of neurons in various brain regions of some autistic individuals that suggest
prenatal or early postnatal maturational problems (Palmen et al 2004). Neuroimaging and head
circumference data suggest that the brain increases significantly more in size between 12 and
48 months in toddlers with autism than in typically developing children (Courchesne and Pierce
2005).
The findings above and the typical clinical presentation strongly suggest that brain
development is aberrant during early postnatal life in individuals with autism. Although the
primary developmental disruptions have not been identified, several factors suggest that early
interventions may be valuable even if they do not address autism’s etiology. These factors
include the redundancy of neurodevelopmental processes, their sensitivity to regulation by a
variety of environmental factors, and evidence of cortical plasticity resulting in compensation
for early developmental alterations. Behavioral treatments that modify the experiences of
affected individuals likely are effective as a consequence of brain plasticity (Dawson and
Zanolli 2003; Kasari et al 2006; Kashinath et al 2006; Whalen et al 2006). Several factors
suggest early interventions may be valuable even if they do not address autism’s etiology.
Neurodevelopment is regulated by multiple environmental factors. In addition, there are many
examples of the cortex being modified to compensate for earlier development alterations.
Pharmacologic interventions provided to young children with autism might have similar
benefits if they are able to 1) target the regulation of early neurodevelopmental processes, 2)
increase opportunities for plasticity, or 3) enhance the affected child’s ability to respond to
behavioral treatments. Several researchers have advocated for pharmacologic treatments that
capitalize on early neural plasticity (Chugani 2005; Rubenstein and Merzenich 2003; Sikich
2001; Whitaker-Azmitia 2001). However, despite the clear value placed on early behavioral
interventions for autism and suggestions to develop developmentally focused pharmacologic
treatments, there has been little enthusiasm for, or study of, early pharmacologic interventions
in autism.
In this review, we seek to move the field forward by presenting a rationale for pharmacologic
treatments that aim to capitalize on brain plasticity in order to compensation for earlier aberrant
development. Further, we describe a multi-pronged approach for future research in this area.
This review is not exhaustive. There are several complementary reviews (Buitelaar and
Bethea and Sikich Page 2













Willemsen-Swinkels 2000; Chugani 2005; Courchesne and Pierce 2005; Keller 2003; Levitt
2003; Palmen et al 2004; Polleux and Lauder 2004; Rubenstein and Merzenich 2003) that
provide a more detailed analysis of individual components synthesized in this review.
NEURODEVELOPMENTAL PROCESSES IMPLICATED IN AUTISM
Reelin
Reelin is a glycoprotein that has a fundamental neurodevelopmental role in the laminar and
columnar organization of the cortex. It interacts with brain-derived neurotrophic factor
(BDNF), to facilitate neuronal and glial migration and organization (Alcantara et al 2006).
Normal cortical development and mature function depend on appropriate levels of reelin
protein, its receptors, and its cytoplasmic adapter, disabled-1 (Dab1) (Deguchi et al 2003).
Reelin levels are very high during late fetal life and gradually decline during late childhood to
achieve a plateau during adolescence (Forster et al 2006). Appropriate levels of serotonin
facilitate the release of reelin. In contrast, excessive serotonin has been shown to reduce reelin
levels leading to disorganized radial accumulations of cortical cells (Janusonis et al 2004).
Interestingly, mice lacking the gene for reelin (RELN) have reduced numbers of cerebellar
Purkinje cells, which is the most frequent neuropathologic finding in autism.
A broad region of chromosome 7 that includes RELN has been linked to autism in several
genome scans (International Molecular Genetic Study of Autism Consortium 2001; Lamb et
al 2005; Schellenberg et al 2006){(Ashley-Koch et al 1999; Hong et al 2000). Evidence of
linkage is heightened in male only families and individuals with language delays. Multiple
genetic association studies have also pointed to a relationship between RELN and autism
(Persico et al 2001; Serajee et al 2006; Skaar et al 2004; Zhang et al 2002a). However, other
investigations have failed to identify a relationship between the RELN gene and autism (Bonora
et al 2003; Devlin et al 2004; Devlin et al 2005; Krebs et al 2002; Li et al 2004; Zhang et al
2002b). Support for reelin’s involvement in autism include finding of decreased RELN mRNA,
decreased reelin protein, decreased mRNA for Dab1, and increased mRNA for one of reelin’s
receptors – the very low density lipoprotein receptor in the frontal and cerebellar cortex of
adults with autism (Fatemi et al 2005; Fatemi et al 2004). Reduced plasma levels of reelin have
been reported in individuals with autism and, their families (Fatemi et al 2002c).
BDNF
BDNF appears to have several developmentally important roles (Galuske et al 1999). BDNF
promotes GABAergic interneuron neurite growth and stimulates the synthesis and release of
GABA (Collazo et al 1992; Marty et al 1996; Matsumoto et al 2006; Nawa et al 1994; Widmer
and Hefti 1994). BDNF also regulates the strength of synaptic inhibition (Rutherford et al
1997; Rutherford et al 1998). BDNF is increased by synaptic activity such that appropriate
synaptic activity increases BDNF release, which further enhances synaptic activity (Castren
et al 1992; Isackson et al 1991; Patterson et al 1992). Each of these BDNF actions favors
maturation of cortical neurons. Excess BDNF leads to premature closure of cortical critical
periods (Huang et al 1999). Thus, excessive levels of BDNF are likely to lead to precocious
maturation, limiting the brain’s ability to refine synaptic processes in response to relevant
experiences (Hanover et al 1999; Huang et al 1999). Such precocious maturation would be
expected to limit a person’s ability to recognize salient stimuli in the environment.
Increases in BDNF have been demonstrated in three separate samples of autistic individuals
relative to typically developing or non neurologically impaired children(Connolly et al 2006;
Miyazaki et al 2004; Nelson et al 2001). Further, both Nelson and Miyazaki found similar
increases in developmentally delayed comparison groups and Nelson also found increases in
other neurotrophic factors (vasoactive intestinal peptide and neurotrophin 4/5). It is notable
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that a follow-up study by Nelson and colleagues, using a double-antibody technique, did not
replicate their original finding (Nelson et al 2006). Overall, this data suggests that findings of
increased BDNF may be incidental or reflect a compensatory response to an earlier
developmental problem, but are unlikely to be etiologically specific for autism.
Cholinergic system
Acetylcholine has two main types of receptors, muscarinic and nicotinic, with different
functions. Muscarinic receptors inhibit the release of gamma-aminobutyric acid (GABA) from
GABAergic interneurons (parvalbumin positive) that regulate background cortical activity.
Nicotinic receptors excite different GABAergic interneurons (cholecystokinin positive) that
fine tune the response of pyramidal cells to specific stimuli (phasic actitvity) (Freund 2003).
Acetylcholine levels appear to gradually increase during childhood, reaching maximal levels
toward the end of the first decade of life and then remain stable (Diebler et al 1979; Herlenius
and Lagercrantz 2004).
Postmortem studies suggest acetylcholine neurotransmission may be abnormal in autistic
adults. In the cortex, binding to both types of acetylcholine receptors is reduced. There is ~30%
less binding to muscarinic M1 receptors and ~70% less binding to nicotinic (nAch) receptors
(Perry et al 2001). Further investigations have also noted reduced mRNA and reduced protein
expression of the α4 subunit of the nAch receptor (Martin-Ruiz et al 2004) (Lee et al 2002).
The cholinergic reductions reported in adults with autism would be expected to perturb
GABAergic signaling, which would have a ripple effect in multiple neurotransmitter systems.
Background (tonic) excitatory activity may increase. Pyramidal cell responses to stimulation
would likely be less well modulated. Disruption of the balance between the GABAergic and
glutamatergic systems would be expected to have significant developmental effects. The
critical and complex interactions between neurotrophins and neurotransmitters are
schematically depicted in Figure 1.
Glutamate neurotransmitter system
Glutamate is the predominant excitatory neurotransmitter in the brain and comprises about half
of all synapses in the forebrain (Herlenius and Lagercrantz 2004). Glutamate has two main
families of receptors: the metabotropic, which are single protein, G-protein coupled receptors,
and the ionotropic receptors comprised of multiple subunits that form ion channels. Although
not examined specifically in autism, dysregulation of the metabotropic glutamate receptor,
mGluR5, has been hypothesized to play an important role in the pathophysiology of Fragile X
syndrome, another neurodevelopmental disorder in which autism is very common (Bear et al
2004). In autism, the iontropic receptors, which include the N-methyl-D-aspartate (NMDA)
receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), and
kainate receptor, have been studied most extensively.
During early development NMDA receptors predominate, whereas in adults, AMPA and
kainate receptors are more active. NMDA receptors, particularly those containing the NR2B
receptor subunit allow increased calcium influx and are more sensitive to stimulation than
AMPA or kainate receptors. Further both excessive activation via excitotoxicity and inhibition
of NMDA receptors have been related to increased cell death (Herlenius and Lagercrantz
2004; Olney 1994). Glutamatergic terminals are over produced during the early postnatal
period and seem to reflect overproduction of synapses that will later be pruned. Through
separate mechanisms, activity at NMDA and kainate glutamatergic receptors promotes neurite
outgrowth and branching (Monnerie and Le Roux 2006; Nguyen et al 2001). In addition,
glutamate’s effects on long-term potentiation via NMDA and long-term depression via AMPA
are likely to play critical roles in synapse development and enhancement. At the neuronal level,
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nonsynaptic release of glutamate facilitates the migration of GABAergic interneurons that
subsequently release GABA which promotes the development and migration of primordial
glutamatergic cells (Manent et al 2006). These processes may augment the development of
excitatory neurotransmission.
There have been multiple reports of linkage disequilibrium to chromosomal regions on
chromosomes 16, 6, and 2 that contain genes important in glutamatergic functioning
(International Molecular Genetic Study of Autism Consortium 2001; Jamain et al 2002; Shuang
et al 2004). 6q21 contains the gene for a kainate receptor, GRIK2, while 16p13 contains the
gene for the NMDA receptor. Chromosome 2 contains the gene SLC25A12, the mitochondrial
aspartate/glutamate carrier. Some association studies also provide evidence of a relationship
between autism and SLC25A12 (Ramoz et al 2004; Segurado et al 2005), while others do not
(Rabionet et al 2006).
Increased plasma levels of glutamate have been found in adults with autism relative to healthy
controls and appear to correlate with levels of social impairment (Shinohe et al 2006). Multiple
amino acids including glutamate were increased in a small sample of children with autism,
their parents and their siblings (Aldred et al 2003). One study of postmortem brain tissue from
adults with autism has demonstrated increased mRNA levels of several glutamate-related
genes: excitatory amino acid transporter 1 (EAAT1) and three of the AMPA receptor subunits.
Interestingly, the increase in AMPA receptor message does not lead to an increase in AMPA
binding. In fact less AMPA binding is observed in the brains of individuals with autism (Purcell
et al 2001). This suggests at least two possibilities; the message is not translated or the subunit
proteins do not function properly for ligand binding. Increased functional EAAT1 would result
in more rapid removal of glutamate from extracellular spaces, which might reduce excitation
at glutamate receptors. Alternatively, increased EAAT1 could reflect upregulation in response
to other factors such as excessive extracellular glutamate.
GABAergic system
GABA binds to two major classes of receptors (GABAA and GABAB), which exhibit diverse
functional activities as a result of multiple subunit combinations. During early periods of
neurogenesis, GABA is present throughout the developing brain. During the first two years of
postnatal life, GABA levels increase dramatically to about twice adult levels, then GABA
levels gradually fall to below adult levels during puberty. During adolescence, GABA levels
increase more slowly to achieve adult levels (Diebler et al 1979; Johnston and Coyle 1981).
Estradiol has been shown to enhance the physiologic response of GABAA receptors during
development (Nunez et al 2005). GABA acts through GABAA receptors to exert neurotrophic
effects on progenitor cells, excitatory neurons, and glia (reviewed (Barker et al 1998; Lauder
et al 1998; Nguyen et al 2001). One type of GABAergic interneuron, the Cajal-Retzius cell, is
an early target of serotonergic afferents. When stimulated by serotonin, Cajal-Retzius cells
produce and secrete reelin (Janusonis 2004). GABA also stimulates the migrations of specific
cortical neurons expressing GABAB receptors (Lopez-Bendito et al 2003).
However, GABA’s most important developmental role may relate to its involvement in synapse
maturation. Prior to maturation of glutamatergic synapses, GABA has both excitatory and
inhibitory actions, as opposed to its exclusively inhibitory actions later (Barker et al 1998).
The differential activity of GABA during fetal life and once glutamatergic synapses have
matured during the early neonatal period may be mediated by the changing composition of
GABAA receptors on cell bodies and dendrites (Ramos et al 2004). The balance between
GABA and glutamate is critical and complex with many cortical cells receiving GABAergic
and glutamatergic inputs at the same postsynaptic site. However, during early development
there are frequent inaccuracies between the presynaptic outputs and their postsynaptic receptors
(Rao et al 2000). GABAergic activity promotes enhanced GABAergic fidelity and indirectly
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reduces glutamatergic mismatch by not reinforcing inappropriate glutamatergic synapses.
Appropriate development of excitatory (glutamate) and inhibitory (GABA) neurotransmission
appears to rely on experience-dependent signaling with a bias towards GABAergic synapse
fidelity (Anderson et al 2004b). Finally, individual types of GABAergic interneurons, which
have unique patterns of input and output, are able to differentially modulate cortical activity
in response to neurotransmitters and neuromodulators (Freund 2003). The coordination
between GABA and glutamate creates and sustains an environment conducive to proper
neurodevelopment. It is essential for appropriate synapse elimination, assembly of architectural
units of cells into mini- and macro-columns, and the development of integrated brain systems.
Changes in GABAergic function have been associated with autism by multiple studies using
different methodologies. Multiple groups have found linkage disequilibrium near or with
GABRB3 (Bass et al 2000; Buxbaum et al 2002; Cook et al 1998; Martin et al 2000). Others
have been unable to replicate these findings (Menold et al 2001; Salmon et al 1999). In addition,
about 3% of some clinical samples of individuals with autism show cytogenetic abnormalities
of chromosome 15q11-q13, which contains genes for three of the GABAA receptor subunits
(GABRB3, GABRA5, GABRG3) (Cook et al 1997b; Dykens et al 2004). These genetic findings
have been extended in a single-nucleotide polymorphism (SNP) study of 14 GABA receptor
genes, which found strong support for the involvement of GABRA4 through interaction with
GABRB1 in vulnerability to autism (Ma, 2005#70). Decreases in GAD65, which converts
glutamate to GABA, and reduced binding of agonists and antagonists to GABAA sites have
been noted (Blatt et al 2001; Fatemi et al 2002b).
Serotonergic system
Serotonin has at least 15 different receptors, which appear to have unique functional activities
and spatial distributions. Specific 5-HT receptor subtypes play pivotal roles during
development. Activation of 5HT1A receptors reduces the length of dendrites and the number
of dendritic spines in hippocampus (Sikich et al 1990). These findings are consistent with the
dendritic changes reported in hippocampal neurons in autism (Bauman and Kemper 1985;
Bauman and Kemper 2005; Raymond et al 1996). 5HT2C receptors appear to be involved in
long-term potentiation in the hippocampus (Tecott et al 1998). 5HT2A receptors are involved
in neuronal differentiation, dendritic maturation and modulation of levels of brain derived
neurotrophic factor (BDNF). The influence of 5HT2A on BDNF may underlie the anti-apoptotic
effect of 5HT2 agonists observed in vitro (Dooley et al 1997; Vaidya et al 1997).
Serotonin has multiple roles that may be important in experience-dependent organization.
During development, serotonin modulates the activity of GABAergic interneurons, particularly
the reelin-releasing Cajal-Retzius cells. In addition, serotonin released by axons projecting
from the thalamus has been demonstrated to play a critical role in the establishment of
appropriate thalamocortical connections. Although thalamic neurons cannot synthesize
serotonin, they transiently express the serotonin transporter, internalize extracellular serotonin,
and incorporate it into synaptic vesicles along with their primary neurotransmitter, glutamate
(Lebrand et al 1996). The function of this serotonergic uptake and co-release remains unclear.
Possible functions include 1) serving as a borrowed transmitter; 2) removing excess serotonin
from the extracellular space until the raphe and glial networks become fully mature, and 3)
creating a gradient of serotonin between the raphe projections and thalamic afferents to guide
neurite extension (Gaspar et al 2003).
In the cortex, serotonin modulates the release of glutamate in response to incoming neuronal
activity by acting both directly on glutamatergic neurons and indirectly on GABAergic
interneurons (Laurent et al 2002; Mooney et al 1994). Serotonin is necessary for the maturation
of thalamic afferents, cortical dendrites and axons. However, too much serotonin results in
immature, widely dispersed dendritic branches (Mooney et al 1994; Salichon et al 2001). Too
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little serotonin results in fewer dendritic spines, abnormally small dendritic arbors and
somatosensory barrels, and reduced synaptic density (Bennett-Clarke et al 1994; Mazer et al
1997; Osterheld-Haas and Hornung 1996; Yan et al 1997). This finding is consistent with the
observation that minicolumns in individuals with autism are narrower than those of individuals
with typical development (Casanova et al 2002b).
One of the earliest and most consistent findings in autism research has been the presence of
plasma and platelet hyperserotonemia in a significant portion of children and adolescents with
autism (Abramson et al 1989; Anderson et al 1987; Leboyer et al 1999; Levy and Bicho
1997; Piven et al 1991; Ritvo et al 1970; Rolf et al 1993; Takahashi et al 1977). Subsequently,
the serotonin transporter gene, SERT or SLC6A4 located on chromosome 17q11.1–12 has been
widely examined. Most studies have focused on the 5-HT transporter gene-linked polymorphic
region (5-HTTLPR), in which the short allele is associated with lower expression of the
serotonin transporter (5-HTT). The specific results of these studies are frequently inconsistent
with one another with some studies finding linkage (IMGSAC 2001; International Molecular
Genetic Study of Autism Consortium 1998; Yonan et al 2003) and others not (Auranen et al
2000; Barrett et al 1999; Betancur et al 2002; Buxbaum et al 2001). Association studies have
had equally confusing results with some observing preferential transmission of the short allele,
which is associated with lower expression of the serotonin transporter (Conroy et al 2004;
Cook et al 1997a; Devlin et al 2005; McCauley J. L. 2004) and others finding preferential
transmission of the long allele (Klauck et al 1997; Yirmiya et al 2001). Although these
discrepancies are not well understood they may be related to differences in the phenotype of
the samples, differences in interactions with other genes prevalent in the particular ethnic
groups studied, or variability in genotyping procedures (Yonan et al 2006). It is also possible
that vulnerability to autism is conferred by more subtle and rare alleles within the gene
(Sutcliffe et al 2005). Further, the autism-related effects of SERT may be evident only if
interactions with other genes or specific environmental conditions are present (D'Amelio et al
2005; Prasad et al 2005).
Perhaps the most relevant evidence for serotonergic involvement in autism has arisen from
Positron Emission Tomography (PET) studies, which allow visualization of serotonin synthesis
in living individuals with autism. PET scans have revealed altered spatial patterns of serotonin
synthesis in a pathway connecting the cerebellum and frontal cortex (Chugani et al 1997). Even
more intriguing is the finding of differences in the developmental pattern of serotonin synthesis
capacity between individuals with autism and controls with typical (Chugani et al 1999).
Normally, serotonin synthesis is 200% the adult levels until about five years of age, and then
gradually falls to adult levels over the next several years (Chugani et al 1999; Herlenius and
Lagercrantz 2004). However, in individuals with autism, serotonin synthesis is very low until
approximately nine years of age and then increases to about 150% of the normal adult levels.
The typical developmental pattern of serotonin synthesis is very similar to the developmental
variations in the number of cortical synapses. Tremendous synaptogenesis occurs during early
childhood followed by gradual synapse elimination during adolescence (Huttenlocher 1979;
Huttenlocher 1990). These relationships are illustrated in Figure 2. There are also parallels
with the temporal pattern of GABA levels (Diebler et al 1979).
Evidence for Altered Brain Morphology in Autism
Neuropathologic studies in autism have been limited by the very small numbers of postmortem
specimens available. Further, many of the donors had comorbid disorders such as epilepsy that
may also be associated with abnormalities in brain structures. Although most studies show
some subtle abnormalities, there are many inconsistencies and several key findings have not
yet been replicated. Observations that require replication include reduced size and increased
packing density of neurons in the limbic system, reduced dentritic trees in hippocampal
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neurons, apparently age-related changes in the diagonal band of Broca and the inferior olive,
agenesis of the facial nucleus, and minicolumn pathology (Bauman and Kemper 1985)
(Bauman and Kemper 1985; Casanova et al 2002a; Casanova et al 2002b; Kemper and Bauman
1993; Raymond et al 1996; Rodier et al 1996). There is more agreement about the presence of
neocortical disorganization in a subset of cases, various olivary abnormalities in 2 studies (67%
of cases) and decreased number and/or size of cerebellar Purkinje cells in 72% of cases (Arin
et al 1991; Bailey et al 1998; Bauman and Kemper 1985; Casanova et al 2002a; Casanova et
al 2002b; Casanova et al 2002c; Fatemi et al 2002a; Fehlow et al 1993; Guerin et al 1996;
Ritvo et al 1986; Rodier et al 1996; Williams et al 1980). Reduction in the number of cerebellar
Purkinje cells, coupled with relatively few abnormalities in the inferior olive, has been
interpreted to imply that the initial brain changes in autism occur prior to birth (Bauman and
Kemper 1985; Bauman and Kemper 2005). Demonstrations of more significant inferior olive
abnormalities have raised questions about whether these abnormalities might be occurring
during early postnatal life (Bailey et al 1998; Harding and Copp 1997; Kern 2003).
Minicolumns in autism
Minicolumns are viewed by some to be the fundamental functional unit within the brain, while
others view macrocolumns, which are typically comprised of 60–80 minicolumns, as the more
fundamental functional unit (Casanova et al 2003; Mountcastle 1997; Rockland 2004). During
typical development, multiple minicolumns are organized into macrocolumns such as the
somatosensory barrel fields or ocular dominance columns in which the minicolumns within a
macrocolumn receive afferent activity that is highly coordinated with respect to spatial location
or physiologic function (Casanova et al 2003; Rubenstein and Merzenich 2003).
One study has found an increase in the number of minicolumns in postmortem specimens from
individuals with autism. The minicolumns were observed to be narrower overall but have a
broader excitatory core with fewer and more widely spaced cells and a significantly reduced
area of peripheral neuropil than is typical (Casanova et al 2002b). These differences suggest
problems both prenatally during neurogenesis with specification of the number of minicolumns
and later during inhibitory interneuron maturation, and dendritic process refinement. These
results seem compatible with Raymond’s observations of poorly elaborated dendritic arbors
in the hippocampus, which also seem likely to reflect difficulties with initial process formation
and maintenance of synaptic contacts.
In autism, the reduction of inhibitory neuropil surrounding the minicolumn core would impair
the minicolumn’s ability to influence its neighbors. Specifically, excitation of narrow
minicolumns will excite a slightly larger number of adjacent minicolumns but will not inhibit
any more distant minicolumns. Consequently, organization into discrete, functionally related
macrocolumns is likely to be more difficult since the edges of these columns will not be readily
detected. In contrast, excitation of typically proportioned minicolumns will lead to excitation
of the adjacent minicolumns and inhibition of those at an intermediate distance so that discrete
functional macrocolumns are formed (Casanova et al 2003). The observation that individuals
with autism often are very detail focused but fail to recognize the broader context of information
may be a functional consequence of narrower minicolumns.
Brain Volume in Autism
Over the past decade, magnetic resonance imaging (MRI) and head circumference studies of
children with idiopathic autism have demonstrated a rapid and developmentally inappropriate
increase in brain volume between 12 and 48 months, that exceeds the typical increases in
volume by 5–10%. Afterwards, there is significant slowing of brain growth at a time when
typically developing youth show significant increases in brain volume (Aylward et al 2002;
Courchesne et al 2003; Gillberg and de Souza 2002; Hazlett 2005; Lainhart et al 1997; Sparks
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et al 2002)reviewed in (Redcay 2005). MRI studies show increases in both gray and white
matter, with white matter changes sometimes appearing more robust with some regional
differences evident. Recent data from MRI and neuropsychological studies suggest a relative
underconnectivity between fronto-parietal regions and interhemispheric loci (Just et al 2006;
Nyden et al 2004; Vidal et al 2006).
A number of potential explanations of the early increase in brain size observed in autism have
been proposed including excessive neurons or glia, an absence of developmentally appropriate
dendritic pruning or overexuberant dendritic arborization. However, the underlying
mechanism has not yet been clarified. It will be particularly important to determine whether
development is simply precocious or whether it is atypical in other ways as well.
The consequences of these early brain changes are not clear. Courchesne and colleagues
(Courchesne and Pierce 2005; Redcay 2005) have hypothesized that the impact will be greatest
on neurons whose development occurs over an extended period, such as those in the frontal
cortex, in contrast to those that mature earlier and more rapidly (primary sensory cortices).
Thus, the effects may be greatest on large integrative neurons, which integrate information
from brain regions that mature earlier and are responsible for higher order cognitive functions.
Aberrations in the development of such integrative neurons might lead to more use of local
processing strategies rather than contextual processing strategies. Such shifts could
theoretically underlie the impaired processing of complex information reported in some
individuals with autism (Minshew et al 2002; Williams et al 2006). Perhaps more importantly,
since these changes in brain volume and connectivity occur at approximately the same time
that the manifestations of autism are becoming apparent, it is possible that therapeutic
interventions provided during this period might be particularly beneficial.
CORTICAL PLASTICITY
The previous sections have summarized many of the molecular events and interactions essential
for typical development and their presumptive relationships to autism. Under optimal
developmental conditions, these processes act in a well integrated manner to organize the cortex
so it effectively discerns salient stimuli, places these stimuli in an appropriate context and acts
upon the resulting information. This key developmental process involves two primary steps
(see reviews (Grossman et al 2003; Levitt 2003; Rubenstein and Merzenich 2003). First, the
inherent width of dendritic arbors appears largely predetermined and supports the
establishment of typical but unrefined topographic patterns that are large, imprecise and
inefficient (Greenough 1987). Cellularly, this is reflected by overproduction of neurons,
neuronal processes and synapses (reviewed by Levitt (2003). During this period, neural
connections form at the rate of almost 40,000 synapses per second.
In the second step, the size, precision and efficiency of these topographic patterns are refined
in a process dubbed “experience-dependent” organization. Such refinement requires
meaningful, coordinated activity between thalamocortical excitatory afferents and both
excitatory and inhibitory intracortical connections to improve signal detection and reduce
extraneous noise (Belmonte et al 2004; Polleux F 2004; Rubenstein and Merzenich 2003). At
a cellular level, in areas of appropriate stimulation, existing synapses are strengthened and the
new synapses and neuritic processes are formed. Concurrently, in areas that receive fewer or
less appropriate inputs, synapses and neuritic processes are eliminated. In nonprimates, the
periods of synapse refinement appear significantly more restricted than in primates who have
subsequent plateau and regressive phases of cortical remodeling (Levitt 2003). The initial
plateau phase in humans has not yet been well defined, but is estimated to be greatest between
two and seven years, with ongoing reorganization prominent through adolescence. There are
marked regional variations in the timing of enhanced organization (Huttenlocher 1979;
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Huttenlocher and Dabholkar 1997). Myelination typically follows the initial periods of synapse
refinement. As discussed earlier, several trophic factors and neurotransmitters, including
BDNF, glutamate, GABA, and serotonin, play critical molecular roles in experience-dependent
organizational refinement.
In addition, synaptic refinement continues to be possible throughout life under limited
conditions (Hensch 2004; Pizzorusso et al 2002; Werker and Tees 2005). When activation of
cholinergic neurons in nucleus basalis is coordinated with meaningful sounds, adult primary
auditory cortex is capable of significant plasticity (Kilgard and Merzenich 1998). Similarly, if
a sensory stimuli is paired with activation of dopaminergic neurons from the ventral tegmental
area, cortical reorganization occurs both in the primary sensory area and in interconnected
secondary auditory cortex of adults (Bao et al 2001).
Sensitive Periods
The concept of critical periods, which may also be known as sensitive periods or optimal
periods, is intricately tied to the processes of structural and functional cortical organization
described above (reviewed by Hensch (Hensch 2004). Initially described by Konrad Lorenz,
critical periods were thought to be well demarcated timepoints when aberrant experiences
resulted in disruption of subsequent typical behavior (Lorenz 1958). This concept has also been
applied to teratology research to define periods when permanent developmental damage occurs
in response to the smallest doses of a toxin (Rice and Barone 2000). Later, the concept was
extended to reflect periods when cortical organization was altered in response to abnormal
stimulation (Hubel and Wiesel 1970; LeVay et al 1980; Wiesel and Hubel 1963; Wiesel and
Hubel 1965). The onset and offset of these periods of plasticity in response to environmental
stimuli were often used to infer the timing of typical maturation of specific functions and
cortical regions. As further work has been done, it has become clear that there may be
remarkable dissynchrony between 1) the time course of a region’s typical maturation, 2) the
period in which its structural organization can be disrupted by abnormal experiences and 3)
the period during which alterations in its structure induced by prior aberrant experiences may
be reversed or overcome. For instance, in visual cortex, the normal development of cortical
columns sensitive to global motion extends to six years. However, the period in which this
organization can be perturbed by deprivation is limited to the first few months of life. In
contrast, visual acuity also normally develops through age six, but is sensitive to damage from
visual deprivation until age eleven. Repair of deprivation induced changes is only possible up
until age seven (Lewis and Maurer 2005). The time course of a region’s sensitive period may
be much shorter than overall development (Johnson 2005) but may also extend well beyond
the window for typical development (Hensch 2005).
Over time, there has also been increasing emphasis on the potential for beneficial plasticity
during the sensitive periods. The dyssynchrony between typical maturation and sensitive
periods and the ability to vary the timing of the optimal plasticity period by environmental
manipulations suggests that it may be possible to overcome early atypical development later
in life. Further, later interventions might be targeted at different molecular processes than those
initially involved in the perturbation. Hence there is great interest in tailoring educational and
medical interventions to exploit these periods of heightened plasticity (Ito 2004;Liao et al
2004;Werker and Tees 2005;Wynder 1998).
Neuroscience research efforts have shifted from identifying specific optimal periods to trying
to understand the biological factors that underlie them and how these factors differ from those
involved in normal developmental processes (Johnson 2005; Katz 1999). There is remarkable
variability in the molecules that regulate developmental plasticity related to different cortical
functions. However, there is emerging evidence that parvalbumin-positive GABAergic
interneurons, whose number and maturation are stimulated by BDNF, play a critical role in the
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determining the close of the optimal period. Specifically, enhanced GABAA function (eg. by
BDNF overexpression or benzodiazepine binding) promotes closure of the optimal period of
plasticity. Reduced GABAA function (eg. by sensory deprivation or knocking out Gad 65
synthesis) prolongs the optimal period of plasticity (Fagiolini et al 2004; Hensch et al 1998;
Huang et al 1999; Iwai et al 2003; Morales et al 2002). In addition, there is strong evidence
that disruption of the extracelluar matrix around neuronal spines is required for plasticity
(reviewed in Hensch, 2005). Release of Tissue plasminogen activator (tPA) in response to
environmental stimuli appears to break down the extracellar matrix (Mataga et al 2004; Mataga
et al 2002; Oray et al 2004).
NEURODEVELOPMENTALLY BASED INTERVENTIONS FOR AUTISM
In the absence of revolutionary discoveries that elucidate the pathophysiology of autism and
lead to accurate diagnosis in utero or infancy, treatments will focus on halting further abnormal
brain development and compensating for prior aberrations. This approach is comparable to
almost all neuropsychiatric disorders whose pathophysiologies are poorly understood as well
as to most somatic medical disorders such as hypertension and diabetes. Conceptually, animal
and human studies of sensitive periods indicate that strategies focused on overcoming early
problems with brain development may be efficacious for the treatment of autism. Early
intensive behavioral interventions (EIBI), which have become the standard of care in autism
and appear to influence overall development and reduce the intensity of core symptomatology,
are based on this strategy, (Aman 2005; McEachin et al 1993; Smith et al 2000).
There are indications that pharmacologic manipulations are equally as capable as behavioral
intervention of producing benefits if provided during sensitive periods. For instance, in the
drosophila model of Fragile X syndrome (FRAX), the mGluR antagonist, 2-methyl-6-
(phenylethynyl)pyridine (MPEP) can reverse associated abnormalities in both brain structure
and behavior if provided during early development, but has no anatomical effects if given later
(McBride et al 2005; Yan et al 2005). In humans with Smith-Lemli-Opitz Syndrome (SLOS),
in whom autism is extremely prevalent, cholesterol supplementation prior to age five reduces
the risk of autism spectrum disorders four-fold (22% versus 88%) compared to later
supplementation (Tierney et al 2001). These two disorders are intriguing because up to 25%
of males with FRAX and 50% of individuals with SLOS meet diagnostic criteria for autism
(Hatton et al 2006; Sikora et al 2006). Thus, treatments that impact experience-dependent brain
organization and are provided during periods of heightened plasticity might compensate for
some developmental abnormalities observed in autism.
Identifying effective treatments
The optimism related to developmental treatments must be tempered by the recognition that
we do not know which pharmacologic interventions will be effective. Further, given the
apparent etiologic heterogeneity of autism, it is possible that different interventions will be
efficacious in different autistic subgroups. Interventions related to molecules or processes
demonstrating clear developmental differences in autism as compared to typical development
may be particularly effective. However, it is also possible that the developmental periods when
such interventions would have been effective will have ended prior to diagnosis of autism. In
that case, it will be important to evaluate treatments targeted toward molecules known to be
important in the brain’s response to developmental perturbations or toward enhancing plasticity
instead. The multiplicity of molecules involved in typical neurodevelopment and the
complexity of their interactions suggest several potential areas in which interventions might
be developed for use in autism.
In designing developmentally-based interventions, it is important to remember several key
challenges. First, the intervention attempts to modulate function in an already perturbed system.
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The levels of almost all neurodevelopmental molecules are precisely regulated in development
and some sort of disruption has already occurred. Investigators cannot assume that provision
of a molecule to autistic individuals during development will have the same impact as provision
of the same molecule to individuals without pre-existing perturbations in the molecule’s
signaling, transport and spatial distribution, or synthesis. For instance, mice with reduced
serotonin synthesis due to 1473G tryptophan hydroxylase-2 homozygosity, show typical
responses to a SSRI only if provided with exogenous tryptophan (Cervo et al 2005). Secondly,
it seems essential to base intervention strategies on brain rather than peripheral findings. For
instance, initial observations of hyperserotonemia led to the conclusion that brain levels of
serotonin were likely to be inappropriately high. Therefore, attempts were made to reduce brain
serotonin through the use of fenfluramine and L-tryptophan depletion. In both these cases,
peripheral serotonin was reduced, but there was no clear benefit from treatment despite several
studies (Campbell et al 1988). Instead, irritability was common with fenfluramine and there
was clear exacerbation of autistic symptoms with tryptophan depletion (McDougle et al
1996). As interventions are proposed and developed, it will be essential to evaluate both
efficacy and safety and tolerability.
Serotonergic interventions have promise
Interventions that enhance serotonergic neurotransmission during early childhood
development appear to have the most immediate potential for eliciting clinically important,
adaptive brain changes in children with autism(Chugani 2002; Chugani 2005). Serotonin plays
a critical role in the development of cortical columns and experience-dependent organization.
Animal work suggests that fluoxetine treatment can prevent functional brain damage from
hypoxic injuries (Chang et al 2006). Further, there is evidence of a developmental abnormality
in serotonin synthesis in some young children with autism. Equally important, FDA-approved
medications which are likely to enhance serotonergic neurotransmission are currently
available. These agents appear to have relatively few adverse effects in human children even
when exposure occurs in utero or during early infancy (Barbey and Roose 1998; Gentile
2005; Isacsson et al 2005; Levinson-Castiel et al 2006; Malm et al 2005; Misri et al 2006;
Moses-Kolko et al 2005; Safer and Zito 2006). The adverse effects that have been noted in
humans are related to withdrawal syndromes, high serum levels or overdoses (Knoppert et al
2006), and possible activation and increased suicidality. Further, the long-term impact from
perinatal and/or early childhood exposure to selective serotonin inhibitors (SSRIs) is not yet
known. It should be noted that three rodent studies in which developing animals were treated
with high doses of SSRI for extended periods observed various late emerging side effects such
presumed anxiety in adult mice (Ansorge et al 2004). In contrast, animals treated with 67%
lower doses from PND1-7 showed no late emerging behavioral effects utilizing the same
assessments (Chang et al 2006).
SSRIs increase availability of serotonin in the synaptic cleft. A recent review of limited data
in the pediatric autism population suggests that the SSRI may have some benefits and appear
safe, but definitive studies do not exist (Kolevzon et al 2006). The most rigorous study,
demonstrated clinical benefit of fluoxetine in the treatment of repetitive behaviors in children
and adolescents with autism (Hollander et al 2004). There is also case series data suggesting
this SSRI may have developmental effects, particularly on language, in young children with
autism (DeLong et al 2002; DeLong et al 1998). In response to the need to move forwards with
the evaluation of promising early interventions, two centers within the NIH-funded Studies to
Advance Autism Research and Treatment (STAART) network have initiated a pioneering
study to examine the developmental impact of fluoxetine treatment in preschool children with
autism. This developmental trial builds upon an initial feasibility study initiated by Drs. Sikich
and DeLong in 1999.
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Regardless, this approach is not without risk. A major impetus for treatment with an SSRI is
our interpretation that there are inadequate amounts of serotonin in the brains of children with
autism. However, this interpretation of Chugani’s seminal PET studies may be incorrect since
the PET studies provide no information about children younger than two years. Serotonin
synthesis in the central nervous system may indeed be inadequate, but may indicate an
adaptation to an earlier developmental period of excessive serotonin synthesis or signaling
(Whitaker-Azmitia 2005). Subsequent use of an SSRI may impede natural compensatory
changes in the developing brain, thereby worsening pathology. Further, serotonin findings in
autism may merely indicate dysfunction in one or more of the neurotransmitters and factors
that facilitate the development of serotonin neurons, receptors, synthesis, or release (see Figure
1). If the autism phenotype is a manifestation of an ‘upstream’ regulator, it is unclear what the
effect of early SSRI treatment will be. Additionally, it is possible with serotonergic treatments,
as with any other treatment provided early in development, that there may be late emerging
side effects such as have been described in some animal studies. Ultimately, it will be essential
to assess the balance between the potential benefits of early treatment on a devastating life long
disorder and the potential risks of ineffective treatment or late-emerging adverse effects.
Other potential developmental pharmacologic interventions
Given our understanding of signaling molecule disruptions in autism, there are several potential
targets in addition to serotonin for developmental interventions in autism, as summarized in
Table 1. The two primary approaches would be to enhance plasticity and promote
compensatory experience related changes or to remediate identified imbalances in
neurotransmission. In the first case, plasticity could potentially be promoted if sensitive periods
were extended or reopened as suggested by Chugani (2005). Reductions in GABAA activity
(e.g. by reduced GABA synthesis, increased degradation or receptor blockade) might have this
effect. However, current GABA antagonists are quite toxic. Blockade of BDNF early in
development might also have this effect. Another strategy might be to disrupt the extracellular
matrix with an agent like tPA in order to create a more permissive environment for synaptic
reorganization. Finally, one could try to augment cholinergic or dopaminergic
neurotransmission in emulation of the animal studies of auditory cortical areas that
demonstrated plasticity by activating the nucleus basalis or ventral tegmental area (Bao et al
2001;Kilgard and Merzenich 1998). Cholinesterase inhibitors or dopamine agonists might act
in these ways.
If one takes the approach of trying to address identified disruptions in neurotransmission,
evidence most strongly supports targeting the serotonin system, as discussed earlier, or the
GABAergic system. The evidence of reduced GABAergic activity coupled with its critical role
in experience-dependent brain organization makes it a primary target. Modulation of GABA
could influence the complex excitatory:inhibitory balance which appears critical to process
and synapse refinement. The availability of approved agents that enhance GABAergic
neurotransmission such as valproic acid, benzodiazepines and estradiol suggest that they may
be appropriate candidates for treating children with autism. Further, in a mouse model that has
deficiencies in SERT, female mice and males treated with estradiol show more normal levels
of serotonin, more complex hippocampal dendrites and fewer anxiety related behaviors than
untreated males or females with ovariectomy or tamoxifen (Ren-Patterson et al 2006). In
addition, if autism reflects an increased ratio of excitation to inhibition as suggested by
Rubenstein and Merzenich (2003), benefits may also be derived from dampening excitatory
neurotransmission. Agents which reduce glutamatergic activity (such as lamotrigine,
topiramate or zonisamide) or enhance activity of the EAAT might be beneficial due to such
actions.
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If on the other hand, autism is related to a hypoglutamatergic state at NMDA receptors as
proposed by Carlsson (Carlsson 1998), highly selective NMDA partial agonists might have
utility as a treatment. Unfortunately, even a regionally selective, highly specific agonist is likely
to be neurotoxic. Carlsson advocates an alternative approach in the augmentation of AMPA
neurotransmission through the use of ampakines. Although no ampakines have yet been
approved by the FDA, a 6 month pilot study in adults with Fragile X syndrome, did not observe
significant adverse effects (Berry-Kravis, personal communication). Carlsson has also
suggested that the primary implication of weak NMDA tone is excessive 5HT2A activity.
Although there is no experimental support from autistic subjects for Carlsson’s hypothesis,
serotonin synthesis is increased during adolescence in individuals with autism and limited use
of serotonergic antagonists, such as the second generation antipsychotics, could be helpful.
Prior medication trials demonstrating some developmental effects in autism
Prior medication trials involving at least 6 children with autism that have demonstrated some
benefit for core symptoms of autism are summarized in Table 2. With the exception of
DeLong’s and Alcami’s studies, none of these trials focused on developmentally targeted
intervention. Consequently, few young children are included. We would expect that benefits
for any of these treatments might be enhanced if younger children were included. It is
noteworthy that the only trials that indicate improvement in communication or social behavior
are open studies. In contrast, reduction in restricted and repetitive behaviors (RRB) have been
demonstrated in multiple trials, the largest of which is a trial of the second-generation
antipsychotic, risperidone. It remains unclear whether this reflects the increased difficulty of
assessing social and communicative behaviors or if it reflects the limitations associated with
brief acute trials and the difficulties maintaining children in double-blind treatment for
extended periods. More comprehensive reviews of pharmacologic treatment studies in autism
are available (Buitelaar and Willemsen-Swinkels 2000;McDougle 2005)
How should evaluation of potential developmental treatments for autism proceed?
In order to validly assess the impact of developmentally focused interventions, it will be
essential to evaluate not only acute effects but also long-term changes in core symptoms and
other developmental abilities, acute and mid-range tolerability, and very late emerging adverse
effects such as those described in animal studies. Because of the limitations of every system
available for study, multiple approaches will be required. The three major approaches that can
be utilized at this time are: 1) animal studies; 2) inclusion of children of all ages in clinical
trials of agents with potential neurodevelopmental applications, and 3) more protracted trials
or post-trial observation periods that allow assessment of long-term consequences of treatment.
Animal models
Although our primary interest is in the initiation of rigorous, developmentally focused
medication trials in autism, the need for extensive animal research in this field cannot be
overstated. The use of animal models may allow us to characterize developmental windows
for treatment and evaluate the appropriate duration of treatment in ways that are impossible in
human studies. Further, animal models will provide the opportunity to rigorously define the
relationships between treatment and changes in activity of different neuromodulators and in
brain structure in ways that are not possible in humans. Such information may facilitate the
design of better treatments. The use of different genetic variants (in mice) may allow us to
formulate ideas about treatment specificity among subgroups of autistic individuals.
However, there are a number of prerequisites to using such models. First, it will be essential
to meticulously define periods of developmental equivalence between mice, nonhuman
primates and humans. It will be crucial to examine the events that are the target of interventions:
1) synaptogenesis, 2) synapse refinement, and 3) the development of the integrative pathways
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presumed to be impaired in autism. This task is complicated by the disparities between primate
and rodent development particularly with regard to extended plateaus of synapse refinement
observed only in primates. There is also extremely limited information about the time course
of these events in humans. In addition, it will be essential to characterize the comparative
pharmacokinetic and pharmacodynamic properties of the candidate agent in animals and
children, rather than adults. Further, animal studies should use pharmacologically relevant,
rather than excessive, doses of the therapeutic agents that are administered by mouth or
transdermally if possible. Blood levels of the medication across species are likely to be more
informative than simple mg/kg or mg/body surface area. Although CSF levels would provide
the most relevant comparison, it is not realistic to measure such levels in autistic children.
Further, it will be important to continue recent efforts to improve the quality of behavioral
assessments in animals models (Garner et al 2006; Nadler et al 2004).
The choice of animal models should be based on the presence of behavioral or
neurodevelopmental differences that reasonably approximate aspects of the autism phenotype
as discussed in several recent reviews (Andres 2002; DiCicco-Bloom et al 2006; Machado and
Bachevalier 2003; Moy et al 2006; Sadamatsu et al 2006). Examples of this might include
inducible FRAX knockouts (Galvez and Greenough 2005), inducible Smith Lemli Opitz
Syndrome (SLOS) knockouts (Waage-Baudet et al 2003), mice that have low rates of brain
serotonin synthesis (Zhang et al 2004) inbred strains that show impaired sociability (Moy et
al 2004), or Garner’s set shifting mouse. SLOS models are particularly interesting because they
exhibit disrupted serotonin and glutamate pathways (Waage-Baudet et al 2003). However, it
seems unlikely that a rodent model will be able to fully capture all of the neurodevelopmental
and behavioral abnormalities present in autism.
To the extent feasible, advances in lower animals should be extended to non-human primates.
Nonhuman primate models allow greater control of environmental factors than human clinical
trials. Further, because nonhuman primates mature more quickly than humans, late emerging
adverse effects can be detected in a shorter period of time. Thus, nonhuman primate models
may be useful to refine the optimal time course of promising human treatments and to define
the late-emerging adverse effects. Although the costs of non-primate human studies are great,
they are probably less than clinical trials in humans and may pose fewer ethical dilemmas.
Future human clinical trials
Integrating younger children into ongoing and currently planned trials is likely to yield
interpretable data about developmental effects most quickly. In trials that include children with
autism across the age range (e.g. 18 months to 18 years), it will be possible to examine the
correlation between age and both beneficial and adverse effects of treatment. Identification of
such relationships will facilitate subsequent trials that more specifically test developmental
intervention hypotheses. Trials should be of sufficient size to stratify for known confounding
factors such as gender, regression, language, and cognitive phenotypes (Bradford et al 2001;
Schellenberg et al 2006). Comprehensive assessment of potential adverse effects will require
active review of body systems and developmental processes rather than volunteered reports of
side effects. Further, it is essential that these trials develop a mechanism for assessing late
emerging adverse effects as well as potential late emerging or enduring benefits.
If an agent is being studied with explicit developmental aims, it is essential that the period of
double-blind treatment be sufficiently long to identify developmental changes. Further, it will
be important to improve assessments of core symptomatology, designing assessments that are
sensitive to change over time. Initial attempts to do this have been undertaken (Cohen et al
2003), but more are needed, particularly assessments that involve direct observation of the
child. In addition, it will be extremely valuable to develop biologic markers of treatment
response; functional magnetic resonance scans that are temporally linked to treatment may
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have promise in this regard. Discontinuation trials that help to define the necessary duration
of treatment will be important in minimizing risks and optimizing safety. Developmentally
focused, trials in children with single-gene disorders with high prevalence of autism or features
of autism, such as Fragile X syndrome, Tuberous Sclerosis, and SLOS, may be particularly
useful if sufficient participants can be enrolled. Such trials would have the advantage of
etiologic homogeneity, but may not generalize to a majority of individuals with idiopathic
autism.
Key ethical issues include: 1) balancing the desire to constrain adjunctive therapies in order to
maximize power to detect meaningful drug effects with the need for adjunctive treatments; 2)
the use of potent agents in children; and 3) denying potentially effective treatment to
participants in the placebo-arm. These concerns are potentially heightened in young children
for whom developmentally directed treatments are likely to be most salient. For instance, the
potential benefits of adjunctive treatments such as EIBI are likely to be greater for very young
children than for older ones because their brains are more plastic. For instance, there are
repeated examples of medications having far greater toxicity in the very young, so potential
risks may well be increased. Issues related to safety are heightened because very few agents
are likely to be approved for use in children and pharmacokinetic testing very seldom includes
the youngest children. However, it is also important to remember that there has been a
tremendous increase in the use of these agents in children and adolescents with autism clinically
despite the absence of any systematic safety information (Witwer and Lecavalier 2005). These
issues are likely to be heightened further if a medication’s benefits are limited to enhancing
development. In that case, it may never be possible to get an indication in adults so that studies
in children can proceed in the traditional manner. If phase II/III trials of such agents are to
proceed, intensive and unbiased safety monitoring will be required. Additional discussion of
the challenges involved in pediatric autism trials is provided in several recent reviews
(Hollander et al 2004) (Aman et al 2004) (Anderson et al 2004a).
Potential strategies to minimize the risks to participants exist. Clear discontinuation guidelines
in response to clinical deterioration must be in place. Likewise, participants should be informed
of their randomization status as soon as their participation is completed by someone who is
not involved in study assessments or data interpretation. Further, placebo-arm participants
would be guaranteed access to ‘active’ treatment either at the conclusion of their study regimen
or early termination of a placebo-arm in order to insure they had access to the potential benefits
of the treatment. It is acknowledged that, if the treatment is only effective during a limited
period of development, these benefits may be diminished by the delay in initiating the
treatment. In addition, given the clear benefits of early environmental and educational
interventions, participants could be allowed access to these therapies as long as there were
efforts to match their use in the treatment and control groups and they were carefully
documented. Properly designed and executed RCTs provide a safe environment in which
interventions can be rigorously evaluated for safety and efficacy (March et al 2004; Sandler
2005) without compromising the best interests of the pediatric participant or quality of the
science.
Conclusions
The evidence that autism is a neurodevelopmental disorder which begins in utero or during the
early postnatal development is extensive. Further, there is increasing awareness of very early
childhood changes in autism. Intervening in autism while the brain is still plastic may provide
important benefits less likely with later treatment. Indeed, the most widely accepted therapy
in autism, early intensive behavioral intervention, is based on this rationale. However, it is
essential to develop a broader range of therapeutic options for use during this critical
developmental period. Pharmacologic interventions are particularly promising because they
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may be more accessible to a larger number of affected children and may be more efficacious
in different subgroups, especially those with low-functioning autism. Advances in our
understanding of autism and normal neurodevelopment have suggested a number of agents
that may positively impact experience-dependent development in autism. Further, there are
extensive and expanding networks of investigators available to develop and test the utility of
promising interventions. It is essential that we undertake the translational research necessary
to make early pharmacologic interventions in autism a reality.
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Figure 1. Neurotransmitters and neuromodulators associated with autism
During prenatal and early infant development, neurotransmitters may have trophic,
morphogenic, and synaptic signaling roles. ‘Maturity’ pathways represent the primary
communications between neurons capable of appropriate receptor-mediated synaptic
neurotransmission. Accordingly, aspects of both pathways may overlap temporally and
spatially during both in utero and childhood development. The complexity and reciprocal
connections of the pathways is notable.
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Figure 2. Developmental Similarities in Serotonin Synthesis and Synapse Number
These two schematics depict the capacity of the brain for serotonin synthesis and the number
of synapses in frontal cortex. They are based on our interpretation of results from other
researchers who examined a limited number of individuals. The serotonin synthesis schematic
(A) is based on PET scans of 30 children with autism and 24 controls (8 siblings and 24 children
with epilepsy) (Chugani et al 1999). The synapse schematic (B) is based on 12 postmortem
specimens (Huttenlocher 1079.) Thus, the exact shapes of the curves is not known.
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Table 1
Hypothetical targets for early interventions in autism.
Target Therapeutic Action Mechanism Drug Class (Candidate Agent)
Increase Ach signaling Decrease Ach catabolism Cholinesterase inhibitor (donepezil)
Increase D1 signaling D1 receptor agonism D1 agonist (dihydrexidine)
Increase dopamine release valproic acid
Increase 5HT1A activation valproic acid
Increase GABAA signaling Allosteric modulation of GABAA receptors Steroids (allopregnanlone, estradiol)
Benzodiazepines
Increase GABA valproic acid
Decrease glutamate signaling Decrease glutamate release lamotrigine
Increase glutamate signaling AMPA receptor agonist Ampakines (CX516)
Decrease 5HT2A signaling 5HT2A antagonism
Increase brain serotonin Decrease 5HT reuptake SSRIs
Decrease BDNF signaling Block TrkB receptors
Decrease BDNF synthesis
Increase reelin signaling Decrease BDNF signaling
Increase reelin synthesis
Upregulate VLDL and ApoE2 receptors
More permissive synaptic
reorganization
Disrupt extracellular matrix associated with
dendrites
tPA
Animal studies suggest certain molecules regulate brain plasticity during development. However, significant caution should be exercised given the spatial
selectivity of these processes in development and the global actions of medications. Some agents, like tPA, will likely require extensive tests in animals
prior to trials in children. Further, it may be a combination of treatments that will produce maximal benefits, while minimizing toxicity.
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